Ming Tsao

Dr. Ming Tsao

orcid

Research Focus & Metrics

Academic Career Length

55Years (1972-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PGPeter Goldstraw
Peter Goldstraw
KCKari Chansky
Kari Chansky
JCJohn Crowley
John Crowley
RRRamon Rami-Porta
Ramon Rami-Porta
HAHisao Asamura
Hisao Asamura
KYK. Yokoi
K. Yokoi

1 February 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
WTWilliam D. Travis
William D. Travis
EBElisabeth Brambilla
Elisabeth Brambilla
MNMasayuki Noguchi
Masayuki Noguchi
ANAndrew G. Nicholson
Andrew G. Nicholson
KGKim R. Geisinger
Kim R. Geisinger
DYDavid Yankelewitz
David Yankelewitz

1 September 2015 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
WTWilliam D. Travis
William D. Travis
EBElisabeth Brambilla
Elisabeth Brambilla
ANAndrew G. Nicholson
Andrew G. Nicholson
YYYasushi Yatabe
Yasushi Yatabe
JAJohn H.M. Austin
John H.M. Austin
IWIgnacio Wistuba
Ignacio Wistuba

18 February 2010 in Nature
Verified
Journal Article
Open access
PDF file
RBRameen Beroukhim
Rameen Beroukhim
CMCraig H. Mermel
Craig H. Mermel
DPDale Porter
Dale Porter
GWGuo Wei
Guo Wei
SRSoumya Raychaudhuri
Soumya Raychaudhuri
MMMatthew Meyerson
Matthew Meyerson
A powerful way to discover key genes with causal roles in oncogenesis is to identify genomic regions that undergo frequent alteration in human cancers. Here we present high-resolution analyses of somatic copy-number alterations (SCNAs) from 3,131 cancer specimens, belonging largely to 26 histological types. We identify 158 regions of focal SCNA that are altered at significant frequency across several cancer types, of which 122 cannot be explained by the presence of a known cancer target gene located within these regions. Several gene families are enriched among these regions of focal SCNA, including the BCL2 family of apoptosis regulators and the NF-κΒ pathway. We show that cancer cells containing amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival. Finally, we demonstrate that a large majority of SCNAs identified in individual cancer types are present in several cancer types.

5 February 2020 in Nature
Verified
Journal Article
Open access
PDF file
Taobo HuTaobo Hu
Taobo Hu
LALauri A. Aaltonen
Lauri A. Aaltonen
FAFederico Abascal
Federico Abascal
AAAdam Abeshouse
Adam Abeshouse
HAHiroyuki Aburatani
Hiroyuki Aburatani
CMChristian von Mering
Christian von Mering
Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1–3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4–5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter4; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation5,6; analyses timings and patterns of tumour evolution7; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity8,9; and evaluates a range of more-specialized features of cancer genomes8,10–18.

24 October 2012 in Nature
Verified
Journal Article
Closed access
PDF file
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
ABAndrew V. Biankin
Andrew V. Biankin
Nic WaddellNic Waddell
Nic Waddell
KKKarin Kassahn
Karin Kassahn
MGMarie-Claude Gingras
Marie-Claude Gingras
SGSean M. Grimmond
Sean M. Grimmond